A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)
Public ClinicalTrials.gov record NCT05064059. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (KEYFORM-007)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the safety and efficacy of coformulated favezelimab/pembrolizumab (MK-4280A) in participants with metastatic colorectal cancer. The study will also compare MK-4280A with the standard of care treatment of regorafenib and TAS-102 (trifluridine and tipiracil). The primary study hypothesis is that coformulated favezelimab/pembrolizumab (MK-4280A) is superior to standard of care with respect to overall survival.
Study identification
- NCT ID
- NCT05064059
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 441 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 10, 2021 (Actual)
- Primary completion
- Aug 15, 2024 (Actual)
- Completion
- Feb 21, 2025 (Actual)
- Last update posted
- May 26, 2026
2021 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Georgetown University Hospital ( Site 1148) | Washington D.C. | District of Columbia | 20007 | — |
| Sibley Memorial Hospital ( Site 1143) | Washington D.C. | District of Columbia | 20016 | — |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 1118) | Marietta | Georgia | 30060 | — |
| Norton Cancer Institute ( Site 1139) | Louisville | Kentucky | 40217 | — |
| Rutgers Cancer Institute of New Jersey ( Site 1105) | New Brunswick | New Jersey | 08903 | — |
| Memorial Sloan Kettering Cancer Center ( Site 1703) | New York | New York | 10065 | — |
| Oregon Health & Science University ( Site 1141) | Portland | Oregon | 97239 | — |
| MUSC Hollings Cancer Center ( Site 1715) | Charleston | South Carolina | 29425 | — |
| The West Clinic, PLLC dba West Cancer Center ( Site 1149) | Germantown | Tennessee | 38138 | — |
| UT Southwestern Medical Center ( Site 1709) | Dallas | Texas | 75390-9063 | — |
| Intermountain Medical Center ( Site 1707) | Murray | Utah | 84107 | — |
| Inova Schar Cancer Institute ( Site 1130) | Fairfax | Virginia | 22031 | — |
| VCU Health Adult Outpatient Pavillion ( Site 1712) | Richmond | Virginia | 23219 | — |
| Blue Ridge Cancer Care ( Site 1718) | Roanoke | Virginia | 24014 | — |
| Seattle Cancer Care Alliance ( Site 1107) | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 137 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05064059, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05064059 live on ClinicalTrials.gov.